Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB-WT) Capital Expenditures (2023 - 2025)

Nuvation Bio (NUVB-WT) has disclosed Capital Expenditures for 3 consecutive years, with $7.7 million as the latest value for Q3 2025.

  • Quarterly Capital Expenditures rose 28792.59% to $7.7 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $8.0 million through Dec 2025, up 4838.27% year-over-year, with the annual reading at $8.0 million for FY2025, 4838.27% up from the prior year.
  • Capital Expenditures for Q3 2025 was $7.7 million at Nuvation Bio, up from $181000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $7.7 million in Q3 2025, with the low at -$27000.0 in Q3 2024.
  • Average Capital Expenditures over 3 years is $823100.0, with a median of $24500.0 recorded in 2023.
  • The sharpest move saw Capital Expenditures tumbled 222.73% in 2024, then skyrocketed 28792.59% in 2025.
  • Over 3 years, Capital Expenditures stood at $13000.0 in 2023, then soared by 1146.15% to $162000.0 in 2024, then surged by 4682.1% to $7.7 million in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $7.7 million, $181000.0, and $72000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.